LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 204

Search options

  1. Article ; Online: Impact of the 2021 CKD-EPI equation on anticancer pharmacotherapy in black and non-black cancer patients.

    Butrovich, Morgan A / Qin, Jiyue / Xue, Xiaonan / Ivy, S Percy / Nolin, Thomas D / Beumer, Jan H

    Cancer letters

    2024  Volume 586, Page(s) 216679

    Abstract: Cancer and kidney disease disproportionately impact Black patients. The CKD- ... ...

    Abstract Cancer and kidney disease disproportionately impact Black patients. The CKD-EPI
    MeSH term(s) Humans ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/therapeutic use ; Cisplatin ; Glomerular Filtration Rate ; Neoplasms/drug therapy ; Renal Insufficiency, Chronic/drug therapy
    Chemical Substances Antineoplastic Agents ; Cisplatin (Q20Q21Q62J)
    Language English
    Publishing date 2024-02-01
    Publishing country Ireland
    Document type Journal Article
    ZDB-ID 195674-7
    ISSN 1872-7980 ; 0304-3835
    ISSN (online) 1872-7980
    ISSN 0304-3835
    DOI 10.1016/j.canlet.2024.216679
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1177: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: The National Cancer Institute's Experimental Therapeutics Clinical Trials Network.

    Ivy, S Percy

    Clinical advances in hematology & oncology : H&O

    2015  Volume 13, Issue 3, Page(s) 144–146

    MeSH term(s) Clinical Studies as Topic ; Government Programs ; Humans ; National Cancer Institute (U.S.) ; United States
    Language English
    Publishing date 2015-03
    Publishing country United States
    Document type Interview
    ZDB-ID 2271951-9
    ISSN 1543-0790
    ISSN 1543-0790
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6505: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Tissue Acquisition in Clinical Trials-Essential for Progress.

    Ivy, S Percy / Abrams, Jeffrey S

    Journal of the National Cancer Institute

    2017  Volume 109, Issue 4

    MeSH term(s) Research Design
    Language English
    Publishing date 2017-04-01
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2992-0
    ISSN 1460-2105 ; 0027-8874 ; 0198-0157
    ISSN (online) 1460-2105
    ISSN 0027-8874 ; 0198-0157
    DOI 10.1093/jnci/djx003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.131: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Triapine Radiochemotherapy in Advanced Stage Cervical Cancer.

    Kunos, Charles A / Ivy, S Percy

    Frontiers in oncology

    2018  Volume 8, Page(s) 149

    Abstract: ... cervical cancer's overactive RNR. Triapine's potent inactivation of RNR arrests cells at the G1/S cell cycle ...

    Abstract Clinical ribonucleotide reductase (RNR) inhibitors have reinvigorated enthusiasm for radiochemotherapy treatment of patients with regionally advanced stage cervical cancers. About two-thirds of patients outlive their cervical cancer (1), even though up to half of their tumors retain residual microscopic disease (2). The National Cancer Institute Cancer Therapy Evaluation Program conducted two prospective trials of triapine-cisplatin-radiation to improve upon this finding by precisely targeting cervical cancer's overactive RNR. Triapine's potent inactivation of RNR arrests cells at the G1/S cell cycle restriction checkpoint and enhances cisplatin-radiation cytotoxicity. In this article, we provide perspective on challenges encountered in and future potential of clinical development of a triapine-cisplatin-radiation combination for patients with regionally advanced cervical cancer. New trial results and review presented here suggest that a triapine-cisplatin-radiation combination may offer molecular cell cycle target control to maximize damage in cancers and to minimize injury to normal cells. A randomized trial now accrues patients with regionally advanced stage cervical cancer to evaluate triapine's contribution to clinical benefit after cisplatin-radiation (clinicaltrials.gov, NCT02466971).
    Language English
    Publishing date 2018-05-07
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2018.00149
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Drug development and registration: Challenges and opportunities in ovarian cancer.

    Ivy, S Percy / Kohn, Elise C

    Cancer

    2017  Volume 123, Issue 14, Page(s) 2597–2599

    MeSH term(s) Carcinoma, Ovarian Epithelial ; Drug Development ; Female ; Humans ; Ovarian Neoplasms
    Language English
    Publishing date 2017-05-12
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 1429-1
    ISSN 1097-0142 ; 0008-543X ; 1934-662X
    ISSN (online) 1097-0142
    ISSN 0008-543X ; 1934-662X
    DOI 10.1002/cncr.30645
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.146: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Effect of removing race from glomerular filtration rate-estimating equations on anticancer drug dosing and eligibility: a retrospective analysis of National Cancer Institute phase 1 clinical trial participants.

    Casal, Morgan A / Ivy, S Percy / Beumer, Jan H / Nolin, Thomas D

    The Lancet. Oncology

    2021  Volume 22, Issue 9, Page(s) 1333–1340

    Abstract: Background: Kidney function assessment by estimated glomerular filtration rate (eGFR) equations, such as the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation, is important to determine dosing and eligibility for anticancer drugs. ... ...

    Abstract Background: Kidney function assessment by estimated glomerular filtration rate (eGFR) equations, such as the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation, is important to determine dosing and eligibility for anticancer drugs. Inclusion of race in eGFR equations calculates a higher eGFR at a given serum creatinine concentration for Black patients versus non-Black patients. We aimed to characterise the effect of removing race from the CKD-EPI equation on dosing and eligibility of anticancer drugs with kidney function cutoffs.
    Methods: We did a retrospective analysis of patients enrolled in phase 1 studies sponsored by the Cancer Therapy Evaluation Program between January, 1995, and October, 2010. eGFR based on creatinine (eGFR
    Findings: Demographics and laboratory values from 340 Black patients (172 men and 168 women) were used. Median age was 57 years (IQR 47-64), median bodyweight was 78·1 kg (67·0-89·8), median body surface area was 1·91 m
    Interpretation: Removing race from the CKD-EPI equation will calculate a lower eGFR for Black patients and exclude more patients from receiving anticancer therapy, which could lead to undertreatment of Black patients with cancer and adversely affect their outcomes.
    Funding: National Institutes of Health.
    MeSH term(s) Antineoplastic Agents/therapeutic use ; Blacks ; Clinical Trials, Phase I as Topic ; Creatinine/blood ; Drug Dosage Calculations ; Eligibility Determination ; Female ; Glomerular Filtration Rate/physiology ; Humans ; Male ; Middle Aged ; National Cancer Institute (U.S.) ; Neoplasms/drug therapy ; Neoplasms/ethnology ; Neoplasms/physiopathology ; Retrospective Studies ; United States
    Chemical Substances Antineoplastic Agents ; Creatinine (AYI8EX34EU)
    Language English
    Publishing date 2021-08-13
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2049730-1
    ISSN 1474-5488 ; 1470-2045
    ISSN (online) 1474-5488
    ISSN 1470-2045
    DOI 10.1016/S1470-2045(21)00377-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5696: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 460: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Drivers of Clinical Trial Participation-Demographics, Disparities, and Eligibility Criteria.

    Mishkin, Grace / Arnaldez, Fernanda / Ivy, S Percy

    JAMA oncology

    2019  Volume 5, Issue 3, Page(s) 305–306

    MeSH term(s) Demography ; European Continental Ancestry Group ; Hispanic Americans ; Humans ; Neoplasms
    Language English
    Publishing date 2019-02-25
    Publishing country United States
    Document type Journal Article ; Comment
    ISSN 2374-2445
    ISSN (online) 2374-2445
    DOI 10.1001/jamaoncol.2018.5949
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article ; Online: Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors.

    Hu, Yiduo / Narayan, Azeet / Xu, Yunshan / Wolfe, Julia / Vu, Dennis / Trinh, Thi / Kantak, Chaitanya / Ivy, S Percy / Eder, Joseph Paul / Deng, Yanhong / LoRusso, Patricia / Kim, Joseph W / Patel, Abhijit A

    JCO precision oncology

    2024  Volume 8, Page(s) e2300289

    Abstract: Purpose: Cell-free circulating tumor DNA (ctDNA) has shown its potential as a quantitative biomarker for longitudinal monitoring of response to anticancer therapies. However, ctDNA dynamics have not been studied in patients with heavily pretreated, ... ...

    Abstract Purpose: Cell-free circulating tumor DNA (ctDNA) has shown its potential as a quantitative biomarker for longitudinal monitoring of response to anticancer therapies. However, ctDNA dynamics have not been studied in patients with heavily pretreated, advanced solid tumors, for whom therapeutic responses can be weak. We investigated whether changes in ctDNA could predict clinical outcomes in such a cohort treated with combined poly(ADP-ribose) polymerase/vascular endothelial growth factor receptor inhibitor therapy.
    Materials and methods: Patients with metastatic pancreatic ductal adenocarcinoma (PDAC), triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), or non-small-cell lung cancer (NSCLC) received up to 7 days of cediranib 30 mg orally once daily monotherapy lead-in followed by addition of olaparib 200 mg orally twice daily. Patients had progressed on a median of three previous lines of therapy. Plasma samples were collected before and after cediranib monotherapy lead-in and on combination therapy at 7 days, 28 days, and every 28 days thereafter. ctDNA was quantified from plasma samples using a multigene mutation-based assay. Radiographic assessment was performed every 8 weeks.
    Results: ctDNA measurements were evaluable in 63 patients. The median baseline ctDNA variant allele fractions (VAFs) were 20%, 28%, 27%, and 34% for PDAC, TNBC, SCLC, and NSCLC, respectively. No association was observed between baseline VAF and radiographic response, progression-free survival, or overall survival (OS). Similarly, no association was found between ctDNA decline and radiographic response or survival. However, an increase in ctDNA at 56 days of combination therapy was associated with disease progression and inferior OS in a landmark analysis.
    Conclusion: ctDNA levels or dynamics did not correlate with radiographic response or survival outcomes in patients with advanced metastatic malignancies treated with olaparib and cediranib.
    MeSH term(s) Humans ; Circulating Tumor DNA/genetics ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Poly(ADP-ribose) Polymerases/therapeutic use ; Triple Negative Breast Neoplasms ; Vascular Endothelial Growth Factor A/therapeutic use ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Biomarkers, Tumor/genetics ; Pancreatic Neoplasms/drug therapy ; Pancreatic Neoplasms/genetics
    Chemical Substances Circulating Tumor DNA ; Poly(ADP-ribose) Polymerases (EC 2.4.2.30) ; Vascular Endothelial Growth Factor A ; Biomarkers, Tumor
    Language English
    Publishing date 2024-02-23
    Publishing country United States
    Document type Journal Article
    ISSN 2473-4284
    ISSN (online) 2473-4284
    DOI 10.1200/PO.23.00289
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article ; Online: Whence High-Grade Serous Ovarian Cancer.

    Kohn, Elise C / Ivy, S Percy

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

    2017  Volume 37, Page(s) 443–448

    Abstract: Our understanding of epithelial ovarian cancer has blossomed, and we now recognize that it is a collection of varied histologic and molecularly different malignancies, many of which may not derive from a true ovarian anatomic precursor. High-grade serous ...

    Abstract Our understanding of epithelial ovarian cancer has blossomed, and we now recognize that it is a collection of varied histologic and molecularly different malignancies, many of which may not derive from a true ovarian anatomic precursor. High-grade serous ovarian cancer (HGSOC) is a unique type of epithelial cancer. It is characterized by nearly universal mutation in and dysfunction of p53, genomic instability rather than driver mutations, advanced stage at onset, and probable fallopian tube epithelium origin, with a serous tubal in situ carcinoma precursor. Germline deleterious mutations in BRCA1 and BRCA2, as well as other less prevalent genes involved in DNA repair, such as PALB2 and RAD51c, are associated with its carcinogenesis and may predict susceptibility to classes of treatment agents, including DNA-damaging agents and DNA repair inhibitors. Loss of function of these genes is associated with homologous recombination dysfunction (HRD). It is now recognized that there may be HGSOC with wild-type BRCA1 and BRCA2 with an identifiable HRD phenotype. Such HRD tumors also may be more susceptible to certain classes of treatments and may be phenotypically detectable with a composite molecular biomarker that has been shown to be predictive for response to PARP inhibitors. Use of this new knowledge of the anatomic and molecular background of HGSOC has led to the rational design of novel combinations of treatment classes to create an HRD-like cellular environment and thus drive treatment benefits.
    MeSH term(s) BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; Carcinoma, Ovarian Epithelial ; Cystadenocarcinoma, Serous/epidemiology ; Cystadenocarcinoma, Serous/genetics ; Cystadenocarcinoma, Serous/pathology ; Cystadenocarcinoma, Serous/therapy ; DNA Repair/genetics ; DNA-Binding Proteins/genetics ; Fallopian Tubes/pathology ; Fanconi Anemia Complementation Group N Protein/genetics ; Female ; Germ-Line Mutation ; Humans ; Neoplasms, Glandular and Epithelial/epidemiology ; Neoplasms, Glandular and Epithelial/genetics ; Neoplasms, Glandular and Epithelial/pathology ; Neoplasms, Glandular and Epithelial/therapy ; Ovarian Neoplasms/epidemiology ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/pathology ; Ovarian Neoplasms/therapy ; Tumor Suppressor Protein p53/genetics
    Chemical Substances BRCA1 Protein ; BRCA1 protein, human ; BRCA2 Protein ; BRCA2 protein, human ; DNA-Binding Proteins ; Fanconi Anemia Complementation Group N Protein ; PALB2 protein, human ; RAD51C protein, human ; TP53 protein, human ; Tumor Suppressor Protein p53
    Language English
    Publishing date 2017-08-26
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2431126-1
    ISSN 1548-8756 ; 1548-8748
    ISSN (online) 1548-8756
    ISSN 1548-8748
    DOI 10.14694/EDBK_174718
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Confronting the Care Delivery Challenges Arising from Precision Medicine.

    Kohn, Elise C / Ivy, S Percy

    Frontiers in oncology

    2016  Volume 6, Page(s) 106

    Abstract: Understanding the biology of cancer at the cellular and molecular levels, and the application of such knowledge to the patient, has opened new opportunities and uncovered new obstacles to quality cancer care delivery. Benefits include our ability to now ... ...

    Abstract Understanding the biology of cancer at the cellular and molecular levels, and the application of such knowledge to the patient, has opened new opportunities and uncovered new obstacles to quality cancer care delivery. Benefits include our ability to now understand that many, if not most, cancers are not one-size-fits-all. Cancers are a variety of diseases for which intervention may be very different. This approach is beginning to bear fruit in gynecologic cancers where we are investigating therapeutic optimization at a more focused level, that while not yet precision care, is perhaps much improved. Obstacles to quality care for patients come from many directions. These include incomplete understanding of the role of the mutant proteins in the cancers, the narrow spectrum of agents, broader mutational profiles in solid tumors, and sometimes overzealous application of the findings of genetic testing. This has been further compromised by the unbridled use of social media by all stakeholders in cancer care often without scientific qualification, where anecdote sometimes masquerades as a fact. The only current remedy is to wave the flag of caution, encourage all patients who undergo genetic testing, either germline or somatic, to do so with the oversight of genetic counselors and physician scientists knowledgeable in the pathways involved. This aspiration is accomplished with well-designed clinical trials that inform next steps in this complex and ever evolving process.
    Language English
    Publishing date 2016-04-27
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2016.00106
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top